Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
Type
Public
HQ
Boulogne-Billancourt, FR
Founded
1929
Size (employees)
4,907 (est)+6%
Website
ipsen.com
Ipsen was founded in 1929 and is headquartered in Boulogne-Billancourt, FR
Report incorrect company information

Ipsen Office Locations

Ipsen has an office in Boulogne-Billancourt
Boulogne-Billancourt, FR (HQ)
65 Quai Georges Gorse
Show all (1)
Report incorrect company information

Ipsen Financials and Metrics

Ipsen Financials

Market capitalization (31-Oct-2017)

8.5 b

Closing share price (31-Oct-2017)

105.2
Ipsen's current market capitalization is €8.5 b.
Show all financial metrics
Report incorrect company information

Ipsen News and Updates

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

* EXELIXIS' PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA​

Cervical Dystonia Management Market 2018 Global Analysis,Opportunities and Forecasts to 2023

WiseGuyReports.Com Publish a New Market Research Report On –“ Cervical Dystonia Management Market 2018 Global Analysis,Opportunities and Forecasts to 2023”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Industrial Furnaces and Ovens Global Market 2018: Key Players – Andritz, Tenova , Despatch, Primetals Technologies, Aichelin Group

Industrial Furnaces and Ovens -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Peptide Therapeutics Market revenue is expected to expand at a CAGR of 10.3% over 2015-2025

Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information